Related Experiment Video
Updated: Jul 8, 2026
11:17
Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
Published on: October 12, 2012
Anticoagulant activity of captopril
Arthur S Brecher1, Sarah J Murrey, Kelly D Gray
1Department of Chemistry, Bowling Green State University, Bowling Green, Ohio 43403, USA. artbrec@bgnet.bgsu.edu
Journal of Cardiovascular Pharmacology
|January 23, 2008
Summary
The antihypertensive drug captopril, and other agents, can affect blood clotting. Captopril prolongs clotting times by altering thrombin and fibrinogen structure, suggesting a novel anticoagulant mechanism.
Area of Science:
- Biochemistry
- Pharmacology
- Hematology
Background:
- Antihypertensive drugs can influence hemostasis.
- Captopril is an angiotensin-converting enzyme inhibitor with a thiol group.
Purpose of the Study:
- To investigate the anticoagulant effects of captopril.
- To elucidate the mechanism of captopril's anticoagulant activity.
Main Methods:
- Assays for prothrombin time (PT) and activated partial thromboplastin time (APTT) using plasma.
- Thrombin clotting assays and thrombin-fibrinogen interaction studies.
- Evaluation of lisinopril and polylysine effects on clotting.
Main Results:
- Captopril prolonged PT and APTT in a dose-dependent manner.
- Captopril directly affected thrombin and fibrinogen activity, suggesting structural alterations.
- Lisinopril and polylysine also demonstrated anticoagulant properties through different mechanisms.
Conclusions:
- Captopril exhibits anticoagulant effects potentially via thiol-disulfide exchange, impacting thrombin and fibrinogen.
- These findings suggest a novel mechanism for captopril's action beyond ACE inhibition.
- Further research is warranted to explore the clinical implications of these anticoagulant properties.
Related Concept Videos
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
01:25Antihypertensive Drugs: Direct Renin Inhibitors
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
01:22Dose-Response Relationship: Potency and Efficacy
The potency of a drug is the measure of its ability to produce a biological response and can be compared by looking at the half-maximum effective concentration or EC50 values of different drugs. A lower EC50 value indicates higher potency of the drug. In the dose–response curve of two antihypertensive drugs, candesartan and irbesartan, a significant difference is observed in their EC50 values. A lower EC50 value for candesartan indicates that it is more potent than irbesartan, as it produces...
01:14Time Course of Drug Effect
The progression of a drug's impact can be analyzed by examining both the concentration-time course and the effect-time course. The concentration-time course is determined by the drug's half-life and is influenced by factors such as its pharmacokinetics, including absorption, distribution, metabolism, and elimination. The effect of the drug is often related to its concentration in the plasma and is calculated using the maximum drug effect and the plasma concentration that generates 50 percent of...